This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of participants who experience an adverse event
Timeframe: Up to ~4 years
Percentage of participants who discontinue due to an adverse event
Timeframe: Up to ~4 years
Number of participants with dose limiting toxicity (DLT) following treatment with HPN328 as monotherapy or in combination with atezolizumab or I-DXd
Timeframe: Up to ~4 years
Maximum concentration (Cmax) of Gocatamig
Timeframe: At designated time points up to ~4 years
Cmax of Atezolizumab
Timeframe: At designated time points up to ~4 years
Cmax of I-DXd
Timeframe: At designated time points up to ~4 years
Time to maximum concentration (Tmax) of Gocatamig
Timeframe: At designated time points up to ~4 years
Tmax of atezolizumab
Timeframe: At designated time points up to ~4 years
Tmax of I-DXd
Timeframe: At designated time points up to ~4 years
Area under the concentration-time curve over the dosing interval t (AUCt) of Gocatamig
Timeframe: At designated time points up to ~4 years
AUCt of atezolizumab
Timeframe: At designated time points up to ~4 years
AUCt of I-DXd
Timeframe: At designated time points up to ~4 years
Area under the concentration-time curve extrapolated to infinity (AUCinf) of Gocatamig
Timeframe: At designated time points up to ~4 years
AUCinf of atezolizumab
Timeframe: At designated time points up to ~4 years
AUCinf of I-DXd
Timeframe: At designated time points up to ~4 years
Terminal half-life (t1/2) of Gocatamig
Timeframe: At designated time points up to ~4 years
t1/2 of atezolizumab
Timeframe: At designated time points up to ~4 years
t1/2 of I-DXd
Timeframe: At designated time points up to ~4 years
Single dose clearance (CL) of Gocatamig
Timeframe: At designated time points up to ~4 years
CL of atezolizumab
Timeframe: At designated time points up to ~4 years
CL of I-DXd
Timeframe: At designated time points up to ~4 years
Steady state maximum concentration (Cmax,ss) of Gocatamig
Timeframe: At designated time points up to ~4 years
Cmax,ss of atezolizumab
Timeframe: At designated time points up to ~4 years
Cmax,ss of I-DXd
Timeframe: At designated time points up to ~4 years
Steady state Ctrough (Ctrough,ss) of Gocatamig
Timeframe: At designated time points up to ~4 years
Ctrough,ss of atezolizumab
Timeframe: At designated time points up to ~4 years
Ctrough,ss of I-DXd
Timeframe: At designated time points up to ~4 years
Steady state time to maximum concentration (Tmax,ss) of Gocatamig
Timeframe: At designated time points up to ~4 years
Tmax,ss of atezolizumab
Timeframe: At designated time points up to ~4 years
Tmax,ss of I-DXd
Timeframe: At designated time points up to ~4 years
Area under the steady state concentration-time curve over dosing interval t (AUCt,ss) of Gocatamig
Timeframe: At designated time points up to ~4 years
AUCt,ss of atezolizumab
Timeframe: At designated time points up to ~4 years
AUCt,ss of I-DXd
Timeframe: At designated time points up to ~4 years
Steady state t1/2 (t1/2,ss) of Gocatamig
Timeframe: At designated time points up to ~4 years
t1/2,ss of Gocatamig with atezolizumab
Timeframe: At designated time points up to ~4 years
t1/2,ss of IDXd
Timeframe: At designated time points up to ~4 years
Steady state CL (CL,ss) of Gocatamig
Timeframe: At designated time points up to ~4 years
CL,ss of Gocatamig with atezolizumab
Timeframe: At designated time points up to ~4 years
CL,ss of I-DXd
Timeframe: At designated time points up to ~4 years
Steady state volume of distribution (V,ss) of Gocatamig
Timeframe: At designated time points up to ~4 years
V,ss of atezolizumab
Timeframe: At designated time points up to ~4 years
V,ss of I-DXd
Timeframe: At designated time points up to ~4 years
Steady state accumulation ratio (AC) of Gocatamig
Timeframe: At designated time points up to ~4 years
AC of atezolizumab
Timeframe: At designated time points up to ~4 years
AC of I-DXd
Timeframe: At designated time points up to ~4 years